Expressing his hardships and triumphs while battling facioscapulohumeral muscular dystrophy, Bonita eighth-grader Sam Ray is one of the winners of the national Scholastic’s annual essay contest.The annual essay, “Breaking Barriers: In Sports, In Life,” was created by Scholastic and Major Baseball League in honor of...
Facio Therapies announced today that it has selected its first series of potential FSHD drug development candidates. This series comprises several families of small-molecule compounds that are associated with a narrowly defined target class. Neither the compound families nor the target class have ever been...
Article originally appeared on sciencedaily.com, November 7, 2017. In a recent paper published in the journal Skeletal Muscle, a Saint Louis University researcher reports success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized by progressive muscle...
Article originally appeared on musculardystrophynews.com, October 10, 2017. Resolaris (ATYR1940) improved the muscle strength of nearly two-thirds of adolescents and young adults with early-onset facioscapulohumeral muscular dystrophy (FSHD), according to final results of a Phase 1/2 clinical trial. The therapy’s maker, aTyr Pharma, presented the findings at the 22nd International Annual Congress of the World Muscle Society...
Post by Chris Carrino June 20th is World FSHD Day. A day of awareness for FSHD, to show we are united for a cure. However, for those of us affected by this disease, June 20th is simply known as - Tuesday. There isn’t a moment of every day that...
This story was originally published on musculardystrophynews.com on April 27, 2017. Resolaris, a protein therapy developed for rare muscle diseases by aTyr Pharma, improved muscle strength and quality of life in a small study of patients with early onset facioscapulohumeral muscular dystrophy (FSHD). These findings, as well as others...
Apabetalone (RVX-208) may become a promising therapy to treat facioscapulohumeral muscular dystrophy (FSHD), according to results announced by the pharmaceutical company Resverlogix. Researchers found this drug acts by switching off the DUX4 gene, which is abnormally active in the muscles of FSHD patients, causing inflammation and...
Starting at the Space Needle in Seattle, our group of cyclists will steadily make their way across the country, covering a grand total of 4,200 miles until they cross the Brooklyn Bridge just 54 days later. The riders will average about 92 miles per day...
October 13, 2016 The Chris Carrino Foundation for FSHD hosted its first annual Casino Night at Mercedes Benz of Massapequa on Saturday, Oct. 8 from 8 p.m. to midnight. The night was filled with games, dancing, special singing performances, silent auction and fundraising. The 200 plus...
We are proud to announce that the Board of Directors of the Chris Carrino Foundation for FSHD has recently awarded a scientific research grant in the amount of $75,625 to Dr. Scott Harper and his team at The Ohio State University. The grant will fund...
Join us for The Chris Carrino Foundation Virtual Gala on October 22, 2020! REGISTER TODAY!